4.5 Article

Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-Increased serum CIIM in subjects with severe radiographic osteoarthritis

Journal

CLINICAL BIOCHEMISTRY
Volume 44, Issue 5-6, Pages 423-429

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2011.01.001

Keywords

Type II collagen; Cartilage; Metalloproteinase; ELISA; Serum CIIM; Neoepitope; Osteoarthritis

Funding

  1. Danish Research Foundation (Den Danske Forskningsfond)
  2. Nordic Bioscience A/S

Ask authors/readers for more resources

Objectives: In joint degenerative diseases, the collagens are degraded by matrix metalloproteinases and protein fragments are released to serum as potential biomarkers. Methods: A collagen type II specific neoepitope, CIIM, was identified (... RDGAAG(1053)) by mass spectrometry. Two ELISAs against the neoepitope were developed. CIIM was measured in cartilage explants in the presence or absence of protease inhibitors. CIIM was measured in OA synovial fluid (n = 51) and serum (n = 156). Knee OA was graded by standard Kellgren-Lawrence (KL) score. Results: The ELISAs showed good technical performance: CV%, < 13%. CIIM release from cartilage explants was blocked by the MMP inhibitor. CIIM was detected in synovial fluid. Furthermore, serum CIIM levels were significantly higher (P < 0.05) in those individuals with mild or severe OA than in those with no OA. Conclusion: We developed a new biomarker for joint degenerative diseases, which we demonstrated was derived from MMP-degraded type II collagen: (C) 2011 The Canadian Society of Clinical chemists. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available